Theralase Technologies Inc. saw a notable increase in its stock price today, gaining 3.85% in the last session.
Theralase Technologies Inc. (TLT.V) experienced a positive trading session, closing at CA$0.27, marking a 3.85% rise. This uptick comes amidst significant financial activities and strategic initiatives from the company, reflecting growing investor interest.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Theralase Technologies Inc.
TLT.V
TLT.V
Theralase Technologies Inc.
WealthAwesomeMarket cap
$78.35M
52W high
$0.41
52W low
$0.15
1W change
-5.56%
Beta
0.59
Analyst Price Targets
Based on analyst covering TLT
Wall Street analysts forecast TLT stock price to rise 174.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.70
+174.5% Upside
Current Price
C$0.26
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TLT's historical volatility
30-Day Vol
54.8%
Annualized
90-Day Vol
96.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.21
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.24 | C$0.20 โ C$0.29 |
| 60 trading days | C$0.23 | C$0.17 โ C$0.30 |
| 90 trading days | C$0.21 | C$0.15 โ C$0.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: With a market cap of CA$76.87 million, Theralase's recent performance highlights its potential for growth, particularly in the biotech sector where innovation can lead to substantial returns.
Theralase Technologies Inc. gains 3.85% in one day
The stock's rise reflects investor optimism following recent financing activities aimed at bolstering clinical research.
Bull case
Theralase recently completed a C$4.8 million financing round, which positions the company to advance its clinical studies and development programs. This funding could drive future revenue growth and boost investor confidence.
Bear case
Despite today's gains, Theralase operates in a highly speculative market with no current profit margin. This makes the company vulnerable to volatility and shifts in investor sentiment.
Recent Developments Fueling Growth
Theralase Technologies recently closed a C$4.8 million offering, which is expected to support its clinical studies and development programs. This funding could be a key driver for future growth, as the company focuses on innovative treatments in the biotech sector.
Market Sentiment and Future Outlook
With a market cap of CA$76.87 million and no current profit margin, Theralase remains a speculative investment. However, today's gains suggest that investors are reacting positively to the company's strategic moves and potential for future breakthroughs in cancer treatment.
Advertisement
